CEO COMMENTS
Gunnar Olsson comments Q2 report 2024
“The positive development at the beginning of the year continues and the second quarter has been very eventful with several important advances. We have started our phase I study with IRL757, entered into a collaboration with MSRD/Otsuka regarding the continued clinical development through clinical Proofof-Concept, received the DSMB’s unanimous recommendation to continue the React-PD study with pirepemat in accordance with plan, and recruited a new CEO for the company.”
LATEST REPORTS
IRLAB receives milestone payment of USD 2.5 million in conjunction with first dosing in a Phase I study with IRL757 in healthy older adults
Gothenburg, Sweden, October 8, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that dosing has been initiated in a Phase I clinical study of the drug candidate IRL757 in healthy adults aged 65 and older. This is the second clinical study with IRL757 and the first study under the collaboration framework with the McQuade Center (MSRD) a member of the global Otsuka family of pharmaceutical companies and will grant IRLAB a milestone payment of USD 2.5 million.
Read More >
Q&A with Kristina Torfgård, CEO, at “Investing in Life Science 2024”
Kristina Torfgård, CEO, interviewed at “Investing in Life Science 2024”, an event hosted by BioStock and VatorSecurities, held on September 12, 2024. In Swedish only.
Read More >FINANCIAL CALENDAR
NEXT
July 10, 2024
Interim Report January – June 2024